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Abstract
Clinical evidence suggests that laryngeal muscle dysfunction is associated with
human aging. Studies in animal models have reported morphological changes
consistent with denervation in laryngeal muscles with age. Life-long laryngeal
muscle activity relies on cytoskeletal integrity and nerve–muscle communica-
tion at the neuromuscular junction (NMJ). It is thought that neurotrophins
enhance neuromuscular transmission by increasing neurotransmitter release.
We hypothesized that treatment with neurotrophin 4 (NTF4) would modify
the morphology and functional innervation of aging rat laryngeal muscles.
Fifty-six Fischer 344xBrown Norway rats (6- and 30-mo age groups) were
used to evaluate to determine if NTF4, given systemically (n = 32) or directly
(n = 24), would improve the morphology and functional innervation of aging
rat thyroarytenoid muscles. Results demonstrate the ability of rat laryngeal
muscles to remodel in response to neurotrophin application. Changes were
demonstrated in fiber size, glycolytic capacity, mitochondrial, tyrosine kinase
receptors (Trk), NMJ content, and denervation in aging rat thyroarytenoid
muscles. This study suggests that growth factors may have therapeutic poten-
tial to ameliorate aging-related laryngeal muscle dysfunction.
Introduction
Neurotrophins are involved in muscle innervation and
differentiation of neuromuscular junctions (NMJs). Clini-
cal studies suggest that age-related laryngeal motor dys-
function may be of neuronal origin (Baker et al. 1998).
In mammals, the neurotrophin family of genes includes:
NTF4, neurotrophin 3 (NTF3), neurotrophin 6 (NT6),
nerve growth factor (NGF), and brain-derived neu-
rotrophin factor (BDNF) (Lai and Ip 2003; Huang and
Reichardt 2012). BDNF, NTF3, and NTF4 are expressed
in skeletal muscle (Gonzalez et al. 1999), and can
modulate synaptic efficiency via tyrosine kinase receptors
(Trk). TrkB is located at both pre- and postsynaptic
NMJs (Gonzalez et al. 1999). This localization presents
an anatomical medium for the effects of NTF4 on
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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neuromuscular morphology and transmission. NTF4
decreases in rat soleus muscle when neuromuscular trans-
mission is blocked by botulinum toxin (Funakoshi et al.
1995). Inhibition of neuromuscular transmission using
botulinum toxin also decreases growth factor expression
(Chevrel et al. 2006). NTF4 decreases after sciatic nerve
transection (Griesbeck et al. 1995). Increases of neu-
rotrophins have been shown with exercise and contrac-
tions induced by sciatic nerve stimulations (Chevrel et al.
2006).
Exogenous NTF4 treatment has been shown to improve
neuromuscular transmission in adult rat diaphragm mus-
cle (Mantilla et al. 2004). This improvement is blocked
by inhibition of TrkB phosphorylation (Zhan et al. 2003).
Neurotrophins may enhance neuromuscular transmission
by increasing neurotransmitter release (Park and Poo
2013). NTF4 also increases Nav and voltage-gated channel
conductance (VGCC) leading to an increase in MAPK
activation and CREB phosphorylation (Lesser and Lo
1995; Lesser et al. 1997). The long-term effect of neu-
rotrophins is thought to come from retrograde transport
of the Trk complex and their regulation of acetylcholine
receptors (AChRs). In sciatic nerve damage, NTF4 treat-
ment reverses the loss of mass in recovering fast muscle
fibers (Simon et al. 2004). Other growth factors have suc-
cessfully been used in humans. Hepatocyte growth factor
(HGF), transforming growth factor beta (TGFB), and
fibroblast growth factor (FGF) have recently been used in
humans for treatment of vocal fold scarring (Hirano et al.
2008, 2012; Branski et al. 2009; Kishimoto et al. 2009).
Collectively, these studies point to the promising effects
of NTF4 as an injectable therapeutic for treatment of
intrinsic laryngeal muscle (ILM) denervation and dysfunc-
tion.
Laryngeal muscles contract rapidly and consistently,
and are susceptible to the deleterious effects of aging. This
activity is thought to contribute to voice problems or dys-
phagia observed in persons over 65 years of age (Trupe
et al. 1984; Ward et al. 1989; Gay et al. 1994; Hagen et al.
1996; Broniatowski et al. 1999; Lundy et al. 1999; Schind-
ler and Kelly 2002). Mechanisms contributing to aging-
related dysfunction include remodeling of the laryngeal
mucosa, muscle fiber loss, atrophy, and changes in muscle
fiber regeneration (Gambino et al. 1990). ILM atrophy
leads to bowing of the vocal folds and inhibiting glottic
closure (Sinard 1998; Baker et al. 2001; McMullen and
Andrade 2009). Studies in animal models have reported
morphological changes consistent with denervation in
ILMs, including distal axonal degeneration, smaller end-
plates, increased variability in endplate architecture, and
decreased axon terminals and ACh vesicular clusters
(Gambino et al. 1990; Perie et al. 1997; Suzuki et al.
2001; Johnson et al. 2013). We hypothesized that
treatment with NTF4 would improve muscle morphology
and reduce age-related denervation in the rat thyroary-
tenoid muscle.
Methods
Animals
Thirty-two Male Fischer 344-Brown Norway F1 rats were
used for systemic studies. There were eight 6-mo controls
receiving saline osmotic pumps (7-day or 14-day) and
eight 30-mo controls used (7-day or 14-day). The NTF4
groups consisted of eight NTF4-treated 6-mo old (7-day
or 14-day) and eight 30-mo old treated rats (7-day or 14-
day). Twenty-four rats were used for direct injection.
Four rats of each age were used as controls. Eight rats
were used in each age group, 6- and 30-mo for direct
injections. The age groups selected represent two points
in the life span curve of this strain (Turturro et al. 1999).
Animals were kept in microisolator cages prior to implan-
tation surgery and given Harlan Teklad food and water
ad libitum. Prior to tissue collection, rats were anes-
thetized with ketamine hydrochloride and xylazine
hydrochloride (100 mg/8 mg per kg body weight injected
intraperitoneal injection) and killed by exsanguination
following a medial thoracotomy. This study was approved
by the University of Kentucky Institutional Animal Care
and Use Committee (IACUC).
Osmotic pump implantation
Ophthalmic ointment was applied and the dorsal aspect
of the neck was shaved and scrubbed with iodine. Body
temperature was maintained with heating pads. Asepti-
cally prepared ALZET osmotic pumps were filled either
with NTF4 or saline, and implanted subcutaneously dor-
sally on the rat posterior to the scapulae using sterile
instruments. First, the pump was inserted into a subcuta-
neous pocket delivery portal to minimize the interaction
between NTF4 and incision healing. A total of 200 ng of
NTF4 in 50 ul saline was delivered for either 7- or
14 days, based on previously administered dosages for
NTF4 and other neurotrophic factors (Simon et al. 2004;
Hirano et al. 2008, 2012; Branski et al. 2009; Kishimoto
et al. 2009). Meloxicam was administered as a preanes-
thetic medication and postoperatively for pain relief. Ani-
mals were observed in their home cages until they
recovered from anesthesia.
Neurotrophin injection procedure
Direct injections of NTF4 were applied into the rats’ left
vocal fold on day one; then, the rats were killed on day
2016 | Vol. 4 | Iss. 10 | e12798
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seven (Welham et al. 2008). Control rats received a 50 lL
direct injection of saline. Rats were sedated with 1–2 mg/
kg acepromazine, placed in an induction chamber at 5%
isoflurane and 1000 mL/min O2 for induction until toe
pinch reflex was lost. The rat was reclined in a supine
position on a platform, and a specula was used to main-
tain the oral patency during the procedure. A 50 mm, 30
gauge, 100-lL syringe (Hamilton) was coupled to a
1.9 mm, 30-degree endoscope (Storz, Tuttlingen, Ger-
many). This allowed for visualization of the vocal folds
and guidance of the syringe. The NTF4 rats received
200 ng in 50 lL saline. This dosage was tolerated with no
side effects. The dosage and length of time prior to killing
was based on our systemic data and doses determined by
other researchers (Simon et al. 2004; Hirano et al. 2008,
2012; Branski et al. 2009; Kishimoto et al. 2009).
Histology and immunohistochemistry
Larynges were dissected, placed in cryprotectant, embed-
ded in OCT, and frozen in 2-methylbutane in liquid
nitrogen. Cross sections of 10 lm thickness were used to
examine the thyroarytenoid muscles. Sections were col-
lected serially; the middle sections on each slide corre-
sponded to the mid-section of each muscle.
For overall morphology and mitochondrial content,
sections were stained with hematoxylin and eosin or with
modified Gomori’s trichrome (Engel and Cunningham
1963; Sheehan and Hrapchack 1980; McMullen and
Andrade 2006). Glycogen content was determined with
the Schiff method (Sheehan and Hrapchack 1980). After
staining, slides were dehydrated in an ethanol series,
cleared with xylene, and mounted in permount. NIH
ImageJ software was used to measure the mean fiber area
(Rasband 1997-2012; McMullen and Andrade 2006).
Cross-sectional fiber area was measured at 409 magnifi-
cation on 3585 fibers. Central nuclei were reported as a
ratio of central to total nuclei. Glycogen content was
reported as percent of glycogen positive to total fibers
from 3936 fibers counted.
To determine denervation, laryngeal sections were fixed
with 4% paraformaldehyde, blocked with goat serum, and
incubated overnight at 4°C with Nav1.5 (Sigma, St. Louis,
MO), followed by an Alexa Fluor conjugated secondary
antibody (Invitrogen, Carlsbad, CA). Heart was used as a
positive control. Thresholding was based on the labeling
intensity of the positive controls. Muscle fibers with
>50% labeling were considered denervated (Kulakowski
et al. 2011). The ratio of denervated to non-denervated
fibers was calculated from three muscle sections per ani-
mal for a total 3630 thyroarytenoid fibers. NMJs were
stained with FITC-labeled a-bungarotoxin (Invitrogen,
Carlsbad, CA) and phalloidin, a marker of muscle actin
(Invitrogen, Carlsbad, CA) to denote fibers (McMullen
and Andrade 2009). We analyzed 59 sections/age from
thyroarytenoid muscles.
To determine TrkB intensity and NMJ quantity, sec-
tions were prepared as the same for denervation staining,
except using antibodies for Trkb (Santa Cruz Biotechnol-
ogy, Inc, Dallas, TX) and mounted with SlowFade con-
taining DAPI (Invitrogen, Carlsbad, CA.). Brain tissue
was used as a positive control; primary antibody was not
added to negative controls. Intensity of TrkB staining was
measured with NIH ImageJ software (Rasband 1997-2012;
Collins 2007; Kulakowski et al. 2011). Images were taken
at the same light intensity. The background was removed
from the images and RGB was measured. Results shown
are integrated intensity values for the green color channel
(TrkB). We analyzed 58 sections/age.
Sections were imaged with a Nikon E6 microscope
equipped with a Digital Sight DS-U3 camera and Ele-
ments software (v 2.0). A total of 20% of histological
images were randomly selected and examined by two
blinded raters for interrater reliability. Interrater reliability
was assessed using the intraclass correlation coefficient
(ICC; two-way, mixed model, single measure). Results
demonstrated a high degree of agreement between raters
(ICC = 0.934 NMJ counts, 0.943 glycogen counts, 0.913
Nav1.5, 0.965 fiber size, and 0.990 central nuclei counts).
Data analysis
Results are presented as means and standard error of the
mean (SEM). Statistical significance was determined by
separate 2 9 2 between-subjects analysis of variance on
the dependent variables of thyroarytenoid fiber size, glyco-
gen content, central nuclei, Nav1.5, TrkB intensity, and
NMJ quantity. The independent variables in the systemic
group were time and age. The independent variables in
the direct injection group were thyroartenoid muscle (left
injected side vs. right noninjected side) and age (6-mo vs.
30-mo). Significant results were followed up with the
Holm-Sidak Method. Several measures from each animal
were averaged for each dependent variable. Animal weight
before and after calculations were determined by within
analysis of variance. The significance level for rejection of
the null hypothesis was set at P ≤ 0.05.
Results
Fiber size changes with age and treatment
Systemic effects
Systemic NTF4 application produced significant differ-
ences in muscle fiber area (Fig. 1). (See Table 1 for
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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systemic statistics). In the 7-day systemic NTF4 group,
mean muscle fiber area significantly increased at 30-mo
compared to controls. In the 14-day systemic NTF4
group, thyroarytenoid muscle fiber area showed no
change at 30-mo compared to controls [F(7, 28) = 4.480,
P < 0.001]. There was no effect of treatment on body
weight (P < 0.05).
Direct injection effects
(See Table 2 for direct injection statistics): The effects of
direct injection of NTF4 into the thyroarytenoid muscles
were determined 7-days post treatment. With direct
NTF4 injection, muscle fiber area at 30-mo was signifi-
cantly decreased compared to controls [F(7, 24) = 5.672,
P < 0.001].
Muscle regeneration
Systemic effects
In the 7-day systemic NTF4 group, thyroarytenoid mean
percent of central nuclei increased for the 30-mo group
compared to aged controls, although the effects did not
reach significance. In the 14-day systemic NTF4 group,
regeneration effects were not observed in the 30-mo ani-
mals compared to controls. There was a significant main
effect of treatment for groups between the 7- and 14-day
treatment groups as a whole [F(7, 24) = 11.22,
P < 0.001].
Direct injection effects
With direct NTF4 injection, mean percent of central
nuclei decreased significantly in the 6-mo injected group
compared to controls. Central nuclei displayed an increas-
ing trend for the 30-mo group compared to controls,
although this effect did not reach significance. There was
a main effect of treatment [F(7,15) = 1.76, P < 0.001)].
Glycogen content
Systemic effects
In the 7-day systemic NTF4 group, percent thyroary-
tenoid glycogen-positive fibers significantly decreased for
the 6- and 30-mo groups compared to aged controls. In
the 14-day systemic NTF4 group, percent thyroarytenoid
glycogen-positive fibers significantly increased for the 6-
and 30-mo groups compared to aged controls [F(7,
28) = 6.209, p < 0.001] (Fig. 2).
Direct injection effects
There was a trend in both treated groups of an increase
of glycogen-positive fibers although the effects did not
reach significance [F(7, 25) = 0.789, P < 0.603].
Figure 1. Changes in fiber size and morphology with NTF4 treatment. Representative hematoxylin stained sections of NTF4 7-day treated
(right) and untreated (left) thyroarytenoid muscles at 30-mo of age. There is an increase in fiber size from control to treated. Treatment with
NTF4 changes the 30-mo fiber size to that of a younger 6-mo old animal. *P < 0.05 versus 30-mo. (scale bar = 25 lm), P < .001). Arrows in
the top picture point to an area of fibrosis. There is also a qualitative decrease of fibrosis in the treated animals.
2016 | Vol. 4 | Iss. 10 | e12798
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Denervation and neuromuscular changes
Systemic effects
In the 7-and 14- day systemic NTF4 groups, the percent
of thyroarytenoid-denervated fibers as measured by
Nav1.5, significantly decreased for the 30-mo group com-
pared to aged controls [F(7, 17) = 25.08, P < 0.001]. At
6-mo, there was a significant increase in NMJ quantity
between the control and treated at 14-days. In the 7- and
14- day systemic NTF4 groups, thyroarytenoid mean
NMJ quantity did not change significantly at 30-mo, but
there was a main effect of treatment [F(7, 28) = 7.33,
P < 0.001]. This may be due to a change in size of the
muscle fiber area (Fig. 3).
Direct injection effects
With direct NTF4 injection, the percent of thyroarytenoid
denervated fibers significantly decreased for the 30-mo
group compared to aged controls [F(7,15) = 14.71,
P < 0.001]. There was a significant increase in NMJ
Table 1. Systemic NTF4 statistics.
6-mo
control
6-mo
NTF4 treated
30-mo
control
30-mo
NTF4 treated
7-Day Treatment Group
n = 4 per group
Fiber size (lm2) 312.51  5.43 314.46  1.89 318.66  2.17 389.03  6.12*
Central nuclei (% central to total nuclei) 2.86  0.21 3.37  0.19 1.37  0.15 4.16  0.15
Nav1.5 (% as total to positive fibers) 28.74  1.19 10.74  1.9* 35.94  1.42 8.42  1.35*
NMJ quantity 42.33  2.11 47.67  5.30 29.5  2.65 27.67  0.62
PASH counts (Glycogen content) 16.83  0.53 0.01  0.003* 6.60  0.17 6.38  0.50*
TrkB intensity 6.45  2.93 10.92  2.05* 25.71  3.66 13.09  2.32*
Average animal weight before (grams) 397.75  29.83 380.75  21.78 582.00  60.60 571.50  67.42
Average animal weight after (grams) 387.00  29.71 385.25  50.76 577.50  50.73 564.00  65.82
14-Day Treatment Group
n = 4 per group
Fiber size (lm) 434.79  9.51 415.25  8.33 425.45  5.07 423.84  4.61
Central nuclei (% central to total nuclei) 5.57  0.71 4.80  1.02 5.29  0.35 4.90  0.28
Nav1.5 (% as total to positive fibers) 21.22  7.53 15.35  1.51* 21.55  0.85 13.73  1.49*
NMJ quantity 28  1.16 45.25  2.14* 30.25  5.45 33.67  3.27
PASH counts (Glycogen content) 0  0 10.16  0.38* 4.35  0.17 9.09  0.11*
TrkB intensity 4.43  1.89 30.53  0.01* 34.54  0.01 43.33  3.93*
Average animal weight before (grams) 329.75  21.23 371.25  15.11 616.25  65.66 585.00  18.85
Average animal weight after (grams) 400.75  22.17 375.25  17.31 580.50  81.28 579.25  19.36
*Significantly different from control.
Table 2. Direct injection statistics.
6-mo
control
n = 4
6-mo
NTF4 injected
n = 8
30-mo
control
n = 4
30-mo
NTF4 injected
n = 8
Fiber size (lm) 328.95  18.55 331.95  12.22 350.64  22.54 322.61  8.51*
Central nuclei (% central to total nuclei) 7.34  0.49 3.87  0.32* 5.39  0.38 7.95  2.42
Nav1.5 (% as total to positive fibers) 3.75  2.35 6.08  0.10 22.65  0.47 9.65  0.25*
NMJ quantity 9.00  3.0 35.67  10.71* 8.13  1.93 11.5  0.87*
PASH counts (Glycogen content) 2.96  1.66 7.38  2.47 5.93  1.21 5.25  0.41
Average animal weight before (grams) 370.65  5.85 360.95  5.85 554.60  1.40 599.40  95.70
Average animal weight after (grams) 373.05  5.05 366.7  7.20 565.45  10.05 602.50  92.9
*Significantly different from control.
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quantity in the 30-mo injected animals. There was also a
main effect of treatment [F(7, 28) = 6.79, P < 0.001].
Mitochondria content
Ragged red fibers were not found in 6-mo controls or in
any NTF4-treated thyroarytenoid muscles, suggesting stable
aerobic capacity with systemic and direct treatment (Fig. 4).
TrkB intensity
In the systemic group, there was a decrease in TrkB
intensity with treatment in the NTF4 7-day 30-month
group. Conversely, in the 14-day group, there was an
increase in TrkB intensity with treatment at 30-mo com-
pared to control [F(7, 28) = 31.26, P =< 0.001)] (Fig. 5).
Discussion
These data provide the first evidence for the effectiveness
of neurotrophins to induce ILM remodeling responses.
We hypothesized that aging ILMs would change following
treatment with NTF4. Changes found in oxidative, meta-
bolic, and glycolytic capacity are consistent with fast-con-
tracting and fatigue-resistant fiber types. A decrease in
mean fiber area in the muscle after direct neurotrophin
treatment is similar to changes in other skeletal muscles
after endurance training.
Figure 2. Changes in aerobic capacity and innervations with NTF4 treatment. Representative glycogen (top) and Nav1.5 (bottom) stained
sections from NTF4 14-day treated (right) and untreated (left) thyroarytenoid muscles at 30-mo of age. Increase of glycogen-positive muscle
fibers indicates a change in respiratory capacity; darker pink fibers are considered glycogen positive. Reduction of denervation with age as
measured by Nav1.5 labeling (green) and phalloidin to denote fibers (red). Left middle panels are representative Nav1.5 (green) and phalloidin
(red) stained sections from untreated thyroarytenoid muscles. The right middle panels are treated muscles. Green insert is Nav1.5 staining
alone. Notice decrease of fibers stained for Nav1.5 after treatment with NTF4. Bottom left micrograph is a positive control consisting of heart
muscle from a 6-month control animal (scale bar = 25 lm), (P < .001).
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The study of ILMs is important to develop effective
interventions or preventative measures in the aging
human. Previous studies have documented alterations in
aging ILMs, including deceases in fiber size, mass, total
number of fibers present, regenerative capacity, NMJ size/
quantity, changes in myosin heavy chain isoforms, and
contractile function (Hagen et al. 1996; McMullen and
Andrade 2006, 2009; Kulakowski et al. 2011; Nishida
et al. 2013). The purpose of this study was to determine
if application of neurotrophins could ameliorate muscle
deterioration associated with age in the ILM.
Our results demonstrated an age-associated increase in
fiber size in the thyroarytenoid muscle after 7 days of sys-
temic NTF4 administration. Previous data show that aging
rat muscle fibers change in the opposite direction com-
pared to the muscles that were treated systemically with
NTF4 (McMullen and Andrade 2006). With direct injec-
tion of NTF4, fiber size decreased at 30-mo of age, similar
to what we have previously observed after laryngeal nerve
stimulation (McMullen et al. 2011). The time and dosage
administration results suggest the need for further
investigation to help explain fiber size change differences
observed between systemic and direct application of NTF4.
With application of neurotrophins in our study, there
is a qualitative decrease in the appearance of fibrosis
(Fig. 1). Fibrosis is a diminution of muscle quality due to
an increase of fat and other noncontractile materials (Ser-
rano et al. 2011). The aging process intensifies the fibrotic
phenotype. In normal fibers, the nuclei are located in the
periphery. A central nucleus within a fiber represents a
nonspecific marker of muscle damage, such as fibrosis,
and/or regeneration. Central nuclei are frequently seen in
dystrophic muscle and during development (Banker and
Engel 2004). With direct NTF4 treatment, the decrease or
lack of change of central nuclei suggests a decrease in
regenerative capacity. However, the nonsignificant effect
for central nucleation in the systemic NTF4 across age
groups in thyroarytenoid may indicate different regenera-
tion capacities with treatment. The diminished regenera-
tive capacity of the thyroarytenoid could be related to a
lack of autophagy or impaired satellite cell function
(McLoon and Wirtschafter 2003; McMullen et al. 2009).
Figure 4. Evidence of red ragged fibers in aging thyroarytenoid muscle and changes with NTF4 treatment. Representative Gomorori’s
trichrome images for overall mitochondria content from control 30-mo (left) and 14-day NTF4-treated muscles (right). There appear to be more
mitochondria clusters as (denoted by black arrows) and red ragged fibers (denoted by red arrows) in untreated aging muscle (scale
bar = 25 lm).
Figure 3. Changes in NMJs with NTF4 treatment: Representative fluorescence microscopy images of NMJs from NTF4 14-day treated
thyroarytenoid muscle sections from different animals labeled with a-bungarotoxin (green) and phalloidin (red) showing that NMJ number
increases with NTF4 treatment at 30-mo (scale bar = 25 lm), (P < .001).
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Alternatively, other researchers have shown that the thy-
roarytenoid regenerates consistently throughout the lifes-
pan to compensate for fiber loss related to disease or
injury, although this capacity appears to decrease with
advancing age (Lee et al. 2012). The static regenerative
capacity in the thyroarytenoid muscle may be detrimental
to key functions of the larynx including respiration, swal-
lowing, and voice and airway protection in the elderly.
Another possibility is that these aging muscles do not
need to regenerate based on the physiological differences
between the muscles (McLoon and Wirtschafter 2003;
McMullen et al. 2009).
Others and we have demonstrated that aging ILMs dis-
play functional evidence of denervation (Perie et al. 1997;
Johnson et al. 2013). A decrease in NMJ abundance
would demonstrate a loss of morphologically defined
innervation points in these muscles. We have previously
demonstrated that NMJs become smaller and less abun-
dant in aging ILMs (Perie et al. 1997). In systemically
NTF4-treated thyroarytenoid muscle, NMJ quantity
increased in the 6-mo 14-day treated group compared to
control. Our current data also show that NTF4 systemic
treatment significantly reduced denervation for the 30-
month animals as measured by Nav1.5 labeling in both
systemic and direct injection groups. NTF4 may thus be
effective for the reinnervation of aging ILMs due to
enhanced muscle morphology. Changes in NMJs and
innervation can also be due to a loss of fast motor units
that can occur with normal aging (Jang and van Remmen
2011). It will be beneficial to determine if contractile
function in the ILMs improves and motor unit number
increases with NTF4 treatment.
Intracellular glycogen content at 6-mo accounts for
~7% of muscle fibers, with the proportion of glycogen-
positive muscle fibers significantly increasing at 30-mo to
27% (McMullen and Andrade 2006), thus indicating a
shift in the muscle cell respiratory physiology with age
(Fig. 2). With NTF4 treatment, glycogen-positive thy-
roarytenoid muscle fibers decreased at 6- and 30-mo for
the 7-day treatment groups. Alternatively, in the 14-day
NTF4 treatment groups, 6-mo and 30-mo animals
showed an increase of glycogen-positive muscle fibers
indicating an overall shift in respiratory capacity. This
implies a differential effect as a factor of treatment time.
Both ages of the direct injection groups also showed a
trend in increasing glycogen content. These data suggest
an interaction effect between changes in muscle aerobic
capacity and treatment duration. Muscles require different
isoenzymes at different ages. Similar results to the 14-day
group finding have been shown in a previous publication
where we electrically stimulated the recurrent laryngeal
nerve (McMullen et al. 2011). If there is a reduction in
glycogen, then there will be an impairment of glycogen
breakdown needed for muscle metabolism. Depletion of
Figure 5. TrkB intensity changes with NTF4 treatment. Representative fluorescence microscopy images of TrkB (Green), DAPI (Blue), and a-
bungarotoxin (Red) from NTF4 14-day control (Left panel) and 14-day treated thyroarytenoid muscle sections (Right panel) showing that TrkB
intensity number increases with NTF4 treatment at 6- and 30-mo (scale bar = 25 lm), (P < .001).
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glycogen can impair metabolism and have a negative
effect on performance. The 14-day systemic group may
have a better response in terms muscle aerobic capacity.
It is possible that NTF4 may have augmented glycogen
loading (Garvey et al. 2015). We did not examine the
content of glycogen intermediates such as maltopentaose
or maltotriose. In future experiments, it would be inter-
esting to test the effects of NTF4 application in rats with
demonstrated alterations in glycogen transport or meta-
bolism.
An additional qualitative observation demonstrated
changes in mitochondrial content (Fig. 4). These changes
have been associated with alterations in muscle fiber size
due to fiber atrophy and fiber loss (Hepple et al. 2004;
Short et al. 2005). In aging ILMs, mitochondrial dysfunc-
tion may also be an important age-related event. Aging
thyroarytenoid muscles from 30-mo old rats contain
fibers with abnormally large mitochondrial accumulations
(ragged red fibers), representing 10.4% (4.5) of counted
muscle fibers (McMullen and Andrade 2006). These qual-
itative findings are suggestive of diminished aerobic
capacity. Ragged red fibers were not found in 6-mo con-
trols or in any NTF4-treated thyroarytenoid muscles, sug-
gesting stable aerobic capacity for these muscles with
treatment.
Finally, we examined the expression of Trkb (Fig. 5)
and found differential effects in TrkB with systemic NTF4
treatment in both the 7-and 14-day groups. It has been
suggested that TrkB expression is reduced at the NMJ
with age (Personius and Parker 2013). These experiments
were conducted in soleus muscle, which is composed of
mostly slow muscle fibers, whereas the ILMs are mostly
fast muscle fibers (Conner et al. 2002). It has been pro-
posed that TrkB may take part in the maintenance and
protection of sensory structures in the laryngeal mucosa
(Yamamoto et al. 2011). The appearance of higher levels
of endogenous TrkB and its increase with treatment sug-
gests the possible enhancement of NMJ transmission with
systemic treatment.
Conclusion
This study examined the effects of neurotrophin applica-
tion in aging rat ILMs. These data display the effect of
neurotrophin use to induce laryngeal remodeling
responses in an animal model. Changes in oxidative,
metabolic, and glycolytic capacity are consistent with
fast-contracting and fatigue-resistant fiber type. Future
study is needed to examine the functional effects of
these neurotrophins on the aging laryngeal muscle. This
study demonstrates that neurotrophins may have thera-
peutic potential on aging-related laryngeal muscle dys-
function.
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